Research and Development

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …

Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …

In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …

AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …

Galenica has announced that it has entered into an agreement to acquire Relypsa in a deal worth $1.53 billion, which …

Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …

Zafgen has announced that it has dropped development of its lead drug candidate, beloranib, in order to focus on a …

PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …

A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …

Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …

Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …